A Study of LY3556050 in Adult Participants With Diabetic Peripheral Neuropathic Pain
Phase 2
Completed
NCT06074562
| Condition | Diabetic Peripheral Neuropathy |
|---|
| Phase | Phase 2 |
|---|
| Sponsor | Eli Lilly and Company |
|---|
| Status | Completed |
|---|
| Enrollment | 404 participants |
|---|
| Interventions | Mazisotine |
|---|
| Start date | Oct 5, 2023 |
|---|
| Completion date | Jun 11, 2025 |
|---|
| Results posted | Jul 30, 2026 |
|---|
Summary
The main purpose of this study is to determine the safety and efficacy of LY3556050 versus placebo in participants with diabetic peripheral neuropathic pain (DPNP). The study will lasts approximately 24 weeks, across 3 study periods.
Mean Change From Baseline in Average Pain Intensity (API) as Measured by Weekly Average of Numeric Rating Scale (NRS) - Bayesian Model Averaging (BMA) Dose-response Model
Baseline, Week 12 · score on a scale
| Placebo | NA score on a scale |
|---|
| Mazisotine 50 mg | NA score on a scale |
|---|
| Mazisotine 200 mg | NA score on a scale |
|---|
| Mazisotine 400 mg | NA score on a scale |
|---|
| Posterior Mean Difference | -0.01 (95% CI -0.27–0.24) |
|---|
Mean Change From Baseline in Average Pain Intensity (API) as Measured by Weekly Average of Numeric Rating Scale (NRS) - Frequentist Repeated Measures (FRM) Analysis
Baseline, Week 12 · score on a scale
| Placebo | -1.58 ± 0.154 score on a scale |
|---|
| Mazisotine 50 mg | -1.68 ± 0.217 score on a scale |
|---|
| Mazisotine 200 mg | -1.25 ± 0.208 score on a scale |
|---|
| Mazisotine 400 mg | -1.69 ± 0.214 score on a scale |
|---|
| p-value | 0.691 |
|---|
| LS Mean Difference | -0.10 (95% CI -0.61–0.40) |
|---|
Open in BENITIONS
View on ClinicalTrials.gov
All trials
This page summarises publicly available data from ClinicalTrials.gov. It is not medical advice and not investment advice. Always consult a qualified healthcare professional.